Breast cancer is not one disease wearing one trench coat. It is a whole cast of subtypes, each with its own habits, mood swings, and talent for causing trouble. That is why immunotherapy has looked brilliant in some patients and shrug-worthy in others. The new review by Shichkin and colleagues maps out that mess in plain terms: breast tumors dodge immune attack by hiding their identity, exhausting T cells, building an unfriendly neighborhood around themselves, and recruiting helpful accomplices like suppressive macrophages, fibroblasts, and myeloid cells (Shichkin et al., 2026).

If your immune system is the nightclub security team, cancer is not just sneaking in through the back. It is bribing the doorman, cutting the camera feed, and somehow filing a protocol amendment halfway through the raid.

A central trick involves immune checkpoints. These are normal biological brakes that stop T cells from going full action-movie hero on healthy tissue. Tumors exploit those brakes by expressing signals such as PD-L1, which basically tells nearby immune cells, "Nothing to see here, move along." Checkpoint drugs try to cut that wire. Sometimes they do. Sometimes the tumor has already built three backup systems.

Why triple-negative breast cancer keeps hogging the immunotherapy spotlight

The subtype that has gotten the most mileage from immunotherapy is triple-negative breast cancer, or TNBC. It tends to carry more immune-cell infiltration and more of the molecular chaos that makes tumors visible to the immune system. In recent years, that has made TNBC the main proving ground for checkpoint inhibitors, especially when paired with chemotherapy (Ran et al., 2025).

But even in TNBC, the old dream of a clean biomarker has not really shown up wearing a cape. PD-L1 helps, but it is not the whole story. Tumor-infiltrating lymphocytes, tumor mutational burden, antigen presentation, and the broader tumor microenvironment all matter too (Shichkin et al., 2026; Wong et al., 2023).

That is where the field has gotten much smarter, and frankly more interesting. A 2023 Nature study showed that response to immunotherapy in TNBC is shaped not just by which cells are present, but by where they are standing and who they are talking to. Spatial organization mattered. Tumors with the right mix of proliferating CD8 T cells, MHC-II-positive cancer cells, and helpful immune interactions were more likely to respond (Wang et al., 2023). Translation: this is not just a head count. It is seating arrangement, office politics, and whether security can actually reach the conference room.

Biomarkers are growing up

One of the more useful themes in this review is that biomarker hunting is moving beyond single stains and single snapshots. Recent reviews and translational studies point toward multi-omic and spatial profiling, meaning researchers are combining pathology, gene expression, immune-cell states, and cell-to-cell geography to predict who might benefit (Harris et al., 2024; Wang et al., 2026).

That matters in the real world because breast cancer has a reputation for being "cold," especially hormone receptor-positive disease. Cold tumors are bad party guests for immunotherapy - fewer active T cells, more suppression, less obvious target practice. New strategies aim to warm things up with radiation, targeted drugs, vaccines, oncolytic viruses, bispecific antibodies, and cell therapies such as CAR-based approaches (Shichkin et al., 2026; Lynch et al., 2025).

This is the part where every trialist starts muttering about endpoints into their coffee. A treatment can look exciting biologically and still fall flat clinically if the right patients are not selected, the combinations are too toxic, or the benefit is modest enough to vanish under the weight of messy disease biology. Breast cancer is very good at humbling anyone who starts polishing a press release too early.

The part worth watching

What makes this paper worth your time is not that it announces one magic bullet. It is that it shows the field finally acting like breast cancer is a complicated ecosystem instead of a single bad cell line with a PR team. The future is probably not one immunotherapy for all breast cancers. It is smarter matching: which subtype, which immune landscape, which biomarker pattern, which combination, and at what point in treatment.

If that works, the payoff is big. More patients could get therapies that actually fit the biology of their tumors instead of being thrown into the usual oncology blender of hope, toxicity, and crossed fingers. Fewer people would take expensive immune drugs that were never going to help them. And the next generation of trials might be built less around broad labels and more around who has a tumor that is finally vulnerable.

That is less flashy than "cancer cured," but also far more believable. In oncology, believable is underrated.

References

Shichkin VP, Morva A, Ulaganathan VK, et al. Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies. Molecular Cancer. 2026. DOI: https://doi.org/10.1186/s12943-026-02655-0

Harris MA, Savas P, Virassamy B, et al. Towards targeting the breast cancer immune microenvironment. Nature Reviews Cancer. 2024;24:554-577. DOI: https://doi.org/10.1038/s41568-024-00714-6

Wang XQ, Danenberg E, Huang CS, et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621:868-876. DOI: https://doi.org/10.1038/s41586-023-06498-3

Ran R, Chen X, Yang J, Xu B. Immunotherapy in breast cancer: current landscape and emerging trends. Experimental Hematology & Oncology. 2025;14:77. DOI: https://doi.org/10.1186/s40164-025-00667-y

Wong RSJ, Ong RJM, Lim JSJ. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. Cancer Drug Resistance. 2023;6:768-787. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC10804393/ ; DOI: https://doi.org/10.20517/cdr.2023.58

Lynch A, West E, Shah N. The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer. npj Breast Cancer. 2025;11:77. DOI: https://doi.org/10.1038/s41523-025-00796-x

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.